Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer
Engineering T cells with chimeric antigen receptors (CARs) has demonstrated remarkable success in eradicating hematological malignancies. In this issue of Immunity, June and colleagues demonstrate the broad antitumor efficacy of a newly-designed CAR targeting the O-linked hypoglycosylated epitopes T...
| Autor principal: | |
|---|---|
| Publicado: |
2016
|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10747613_v44_n6_p1248_Blidner http://hdl.handle.net/20.500.12110/paper_10747613_v44_n6_p1248_Blidner |
| Aporte de: |
| id |
paper:paper_10747613_v44_n6_p1248_Blidner |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_10747613_v44_n6_p1248_Blidner2023-06-08T16:05:10Z Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer Mariño, Karina V. antigen artificial receptor carbohydrate antigen carcinoembryonic antigen chimeric antigen receptor cytotoxic T lymphocyte antigen 4 epidermal growth factor receptor 2 epitope gamma interferon ganglioside GD2 glycosylated antigen glycosylated protein interleukin 2 lentivirus vector mesothelin monoclonal antibody mucin 1 programmed death 1 ligand 1 programmed death 1 receptor single chain fragment variable antibody theratope Tn antigen tumor marker unclassified drug acute lymphoblastic leukemia antineoplastic activity breast cancer cancer immunization cancer immunotherapy cell therapy clinical trial (topic) cytotoxicity drug targeting genetic engineering hematologic malignancy human lymphatic system tumor malignant transformation neoplasm nonhuman priority journal Short Survey solid tumor T cell leukemia T lymphocyte glycosylation immunology neoplasm Glycosylation Humans Neoplasms T-Lymphocytes Engineering T cells with chimeric antigen receptors (CARs) has demonstrated remarkable success in eradicating hematological malignancies. In this issue of Immunity, June and colleagues demonstrate the broad antitumor efficacy of a newly-designed CAR targeting the O-linked hypoglycosylated epitopes Tn and sialyl-Tn on cancer-associated MUC-1. Engineering T cells with chimeric antigen receptors (CARs) has demonstrated remarkable success in eradicating hematological malignancies. June and colleagues demonstrate the broad antitumor efficacy of a newly-designed CAR targeting the O-linked hypoglycosylated epitopes Tn and sialyl-Tn on cancer-associated MUC-1. © 2016 Elsevier Inc. Fil:Mariño, K.V. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. 2016 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10747613_v44_n6_p1248_Blidner http://hdl.handle.net/20.500.12110/paper_10747613_v44_n6_p1248_Blidner |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
antigen artificial receptor carbohydrate antigen carcinoembryonic antigen chimeric antigen receptor cytotoxic T lymphocyte antigen 4 epidermal growth factor receptor 2 epitope gamma interferon ganglioside GD2 glycosylated antigen glycosylated protein interleukin 2 lentivirus vector mesothelin monoclonal antibody mucin 1 programmed death 1 ligand 1 programmed death 1 receptor single chain fragment variable antibody theratope Tn antigen tumor marker unclassified drug acute lymphoblastic leukemia antineoplastic activity breast cancer cancer immunization cancer immunotherapy cell therapy clinical trial (topic) cytotoxicity drug targeting genetic engineering hematologic malignancy human lymphatic system tumor malignant transformation neoplasm nonhuman priority journal Short Survey solid tumor T cell leukemia T lymphocyte glycosylation immunology neoplasm Glycosylation Humans Neoplasms T-Lymphocytes |
| spellingShingle |
antigen artificial receptor carbohydrate antigen carcinoembryonic antigen chimeric antigen receptor cytotoxic T lymphocyte antigen 4 epidermal growth factor receptor 2 epitope gamma interferon ganglioside GD2 glycosylated antigen glycosylated protein interleukin 2 lentivirus vector mesothelin monoclonal antibody mucin 1 programmed death 1 ligand 1 programmed death 1 receptor single chain fragment variable antibody theratope Tn antigen tumor marker unclassified drug acute lymphoblastic leukemia antineoplastic activity breast cancer cancer immunization cancer immunotherapy cell therapy clinical trial (topic) cytotoxicity drug targeting genetic engineering hematologic malignancy human lymphatic system tumor malignant transformation neoplasm nonhuman priority journal Short Survey solid tumor T cell leukemia T lymphocyte glycosylation immunology neoplasm Glycosylation Humans Neoplasms T-Lymphocytes Mariño, Karina V. Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer |
| topic_facet |
antigen artificial receptor carbohydrate antigen carcinoembryonic antigen chimeric antigen receptor cytotoxic T lymphocyte antigen 4 epidermal growth factor receptor 2 epitope gamma interferon ganglioside GD2 glycosylated antigen glycosylated protein interleukin 2 lentivirus vector mesothelin monoclonal antibody mucin 1 programmed death 1 ligand 1 programmed death 1 receptor single chain fragment variable antibody theratope Tn antigen tumor marker unclassified drug acute lymphoblastic leukemia antineoplastic activity breast cancer cancer immunization cancer immunotherapy cell therapy clinical trial (topic) cytotoxicity drug targeting genetic engineering hematologic malignancy human lymphatic system tumor malignant transformation neoplasm nonhuman priority journal Short Survey solid tumor T cell leukemia T lymphocyte glycosylation immunology neoplasm Glycosylation Humans Neoplasms T-Lymphocytes |
| description |
Engineering T cells with chimeric antigen receptors (CARs) has demonstrated remarkable success in eradicating hematological malignancies. In this issue of Immunity, June and colleagues demonstrate the broad antitumor efficacy of a newly-designed CAR targeting the O-linked hypoglycosylated epitopes Tn and sialyl-Tn on cancer-associated MUC-1. Engineering T cells with chimeric antigen receptors (CARs) has demonstrated remarkable success in eradicating hematological malignancies. June and colleagues demonstrate the broad antitumor efficacy of a newly-designed CAR targeting the O-linked hypoglycosylated epitopes Tn and sialyl-Tn on cancer-associated MUC-1. © 2016 Elsevier Inc. |
| author |
Mariño, Karina V. |
| author_facet |
Mariño, Karina V. |
| author_sort |
Mariño, Karina V. |
| title |
Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer |
| title_short |
Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer |
| title_full |
Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer |
| title_fullStr |
Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer |
| title_full_unstemmed |
Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer |
| title_sort |
driving cars into sweet roads: targeting glycosylated antigens in cancer |
| publishDate |
2016 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10747613_v44_n6_p1248_Blidner http://hdl.handle.net/20.500.12110/paper_10747613_v44_n6_p1248_Blidner |
| work_keys_str_mv |
AT marinokarinav drivingcarsintosweetroadstargetingglycosylatedantigensincancer |
| _version_ |
1768542562237284352 |